Resources

Shaun Grady is becoming BIA chair, effective from January 2026, in another week of innovation for our sector.

In the third part of our series on Industrial Strategy, Lewis Miles and Maddie Cass provide a deep dive into the Digital and Technologies Sector Plan, analysing how these policies aim to foster growth in the UK's life sciences and engineering biology sectors. We also look forward to strengthening relations and gaining key insight from our US sister organisation with BIO's upcoming UK visit.

 In this blog, Abby Clark builds on a round table the BIA hosted with Chi Onwurah MP and Newcastle life science companies to explore the landscape and the drivers which make the sector strong, yet undervalued. 

The pioneering gene therapy company is consolidating its UK office and lab space to form a central innovation hub at 20 Water Street.

Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment; Initial proof-of-concept data expected in second half of 2026

Tailor Bio announced the publication of a pivotal study demonstrating the power of chromosomal instability (CIN) signatures to predict resistance to widely used chemotherapy drugs across multiple cancer types.

BIA has released a new explainer highlighting why the UK is well-positioned to lead in functional genomics, thanks to its unparalleled research capacity and exceptional talent pool.

Positive news ahead of Spending Review (join our webinar this Friday), latest on getting pensions investment into UK life sciences and more!

In this blog Richard Turner, the new vice chair of FTAC, examines the UK's overhauled R&D tax regime, which provides competitive incentives and a stable fiscal framework.

Pension capital is unlocked in time for BIA's Parliament Day this Wednesday.

WHO members adopted the pandemic preparedness accord as an international treaty at the World Health Assembly. In this blog, Senior Policy and Public Affairs Manager Linda Bedenik looks at what the agreement means for life sciences.

This is a move that speaks to the strength of BIA and the vitality of the UK life sciences ecosystem.

New studies presented at the American Thoracic Society (ATS) Conference this week validate e-Lung as an accurate tool to identify progressive pulmonary fibrosis.

This week I highlight innovation across the sector and call on pension funds to be mandated to support our industry.

European Medicines Agency (EMA) has granted orphan drug designation to PS-002, Purespring’s lead programme, in IgA nephropathy (IgAN).

In this blog, Dr Emma Lawrence, Head of data tech policy and public affairs at BIA, writes about the UK government's recent £600 million initiative to launch a Health Data Research Service which aims to revolutionize access to NHS data and tackle longstanding governance and technical hurdles.